News | August 05, 2024
Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
Subscribe To Our Newsletter & Stay Updated
